ESR1 and ductal breast carcinoma in situ: There is poor uptake of standard primary prevention interventions (especially the selective estrogen receptor modulators tamoxifen and raloxifene), particularly in women with no prior diagnosis of ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), or atypical ductal hyperplasia (ADH).